Rapt Therapeutics (NASDAQ:RAPT) Given “Equal Weight” Rating at Wells Fargo & Company

Wells Fargo & Company reiterated their equal weight rating on shares of Rapt Therapeutics (NASDAQ:RAPT) in a report published on Tuesday, Marketbeat.com reports. Wells Fargo & Company currently has a $58.00 target price on the stock.

Several other equities research analysts have also recently issued reports on RAPT. Barclays lowered their target price on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Piper Sandler lowered shares of Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price target on the stock. in a research report on Tuesday. TD Cowen reaffirmed a “hold” rating on shares of Rapt Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Rapt Therapeutics from $55.00 to $57.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Finally, Guggenheim cut Rapt Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $48.22.

Rapt Therapeutics Trading Up 64.0%

NASDAQ:RAPT opened at $57.57 on Tuesday. The stock has a 50 day moving average of $33.31 and a two-hundred day moving average of $23.72. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $57.61. The firm has a market cap of $1.60 billion, a P/E ratio of -5.21 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last released its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.23. On average, research analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Institutional Trading of Rapt Therapeutics

Several institutional investors have recently made changes to their positions in RAPT. Dimensional Fund Advisors LP acquired a new position in Rapt Therapeutics in the third quarter valued at approximately $231,000. Bridgeway Capital Management LLC increased its stake in Rapt Therapeutics by 32.0% during the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after acquiring an additional 5,000 shares during the last quarter. UBS Group AG raised its position in Rapt Therapeutics by 680.3% in the third quarter. UBS Group AG now owns 28,808 shares of the company’s stock valued at $743,000 after purchasing an additional 25,116 shares during the period. Millennium Management LLC lifted its stake in shares of Rapt Therapeutics by 75.2% in the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company’s stock valued at $1,013,000 after purchasing an additional 16,854 shares during the last quarter. Finally, Susquehanna International Group LLP grew its holdings in shares of Rapt Therapeutics by 173.4% during the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock worth $1,170,000 after purchasing an additional 28,782 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Trending Headlines about Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to acquire Rapt in a definitive deal valuing the company at about $2.2 billion (~$58.00 per share), providing a cash exit at a sizable premium to recent trading and directly causing the stock’s sharp rise. Article Title
• Positive Sentiment: Multiple outlets highlight that GSK gains a late‑stage food allergy antibody (ozureprubart) from Rapt’s pipeline — a strategic fit that supports the acquisition rationale and the deal premium. Article Title
• Positive Sentiment: Rapt’s investors and prior backers benefit: Forbion confirms this is a successful exit from its Growth Fund III, which validates the deal’s value to venture/early investors. Article Title
• Neutral Sentiment: Analysts have mostly left ratings and price targets around the announced deal price (Wells Fargo equal weight with $58 PT; Lifesci/TD Cowen hold), which implies limited near‑term upside beyond the acquisition consideration. Article Title
• Negative Sentiment: Several law firms have announced investigations or shareholder class‑action interest probing whether Rapt’s board negotiated a fair price, which could lead to litigation, procedural delays or settlement costs ahead of closing. Investors should monitor any formal complaints. Article Title
• Neutral Sentiment: Coverage pieces and buy/analysis notes (e.g., Seeking Alpha, The Motley Fool) frame Rapt as an attractive biotech target highlighting its long‑acting IgE candidate; useful context for strategic rationale but secondary to the binding deal terms. Article Title

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.